Ipamorelin

Ipamorelin – Selective Growth Hormone Secretagogue Research Peptide

Synthetic Pentapeptide for Ghrelin Receptor Signaling, Growth Hormone Secretion, GH–IGF-1 Axis & Neuroendocrine Research

Ipamorelin is a synthetic pentapeptide belonging to the growth hormone secretagogue (GHS) family. It is primarily investigated for its ability to stimulate growth hormone (GH) release through the growth hormone secretagogue receptor, commonly known as GHS-R1a or the ghrelin receptor.

Ipamorelin attracted scientific attention because early experimental studies demonstrated relatively selective stimulation of GH secretion compared with certain other growth hormone-releasing peptides.

Unlike recombinant human growth hormone, Ipamorelin does not act as a replacement for GH. Instead, it stimulates the body's endogenous growth hormone secretory machinery in responsive experimental systems.

Its principal research applications include:

• Growth hormone secretagogue receptor pharmacology

• Ghrelin receptor signaling

• Anterior pituitary GH secretion

• GH–IGF-1 endocrine regulation

• Neuroendocrine receptor selectivity

• ACTH and cortisol response comparisons

• Peptide structure–activity relationships

• Pituitary hormone signaling

• Growth hormone secretagogue development

• Experimental gastrointestinal motility research

Although Ipamorelin has demonstrated GH-releasing activity in preclinical models, its effectiveness and long-term safety for muscle growth, fat loss, anti-aging, athletic performance or general wellness have not been established in humans.

ICAME Pharmacy Ipamorelin is intended strictly for laboratory research and development purposes. Not for human or veterinary use.

What Is Ipamorelin?

Ipamorelin is a synthetic peptide containing five amino acid residues.

It belongs to a class of compounds called growth hormone secretagogues, which stimulate the secretion of endogenous growth hormone.

Growth hormone is produced by somatotroph cells in the anterior pituitary gland.

Its release is regulated by several interacting systems, including:

• Growth hormone-releasing hormone (GHRH)

• Somatostatin

• Ghrelin and GHS-R1a signaling

• Circulating IGF-1

• Metabolic and nutritional signals

• Sleep-associated endocrine rhythms

Ipamorelin primarily acts through the ghrelin receptor-associated pathway.

This mechanism differs from that of native GHRH, which acts through the GHRH receptor, and from recombinant HGH, which directly activates growth hormone receptors in peripheral tissues.

Ipamorelin is best understood as an experimental endocrine signaling compound, rather than a clinically established growth hormone treatment.

Ipamorelin Molecular Structure

Ipamorelin is a short synthetic peptide with five residues, including nonstandard amino acid structures.

Molecular Characteristics

Compound Name: Ipamorelin

Development Code: NNC 26-0161

Classification: Growth Hormone Secretagogue / Synthetic Pentapeptide

Peptide Length: 5 Amino Acid Residues

Amino Acid Sequence: Aib–His–D-2-Nal–D-Phe–Lys–NH₂

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: Approximately 711.9 g/mol

CAS Number: 170851-70-4

Primary Receptor: GHS-R1a

Receptor Family: G Protein-Coupled Receptor

Principal Research Pathway: Gq/11–PLC–IP₃/DAG–Ca²⁺

Primary Biological Endpoint: Growth Hormone Secretion

Related Endocrine Axis: GH–IGF-1

These molecular characteristics describe the Ipamorelin peptide itself. Acetate and other salt forms may have different analytical composition and mass characteristics.

Ipamorelin Amino Acid Sequence

The commonly reported Ipamorelin sequence is:

H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Its five residues are:

The peptide contains a C-terminal amide group.

Why Is the Structure Important?

The inclusion of nonstandard residues contributes to the compound's receptor-binding properties and distinguishes it from naturally occurring peptide hormones.

The D-configured amino acids also influence its three-dimensional characteristics.

These structural features are important in experimental studies of receptor selectivity and peptide pharmacology.

A correct sequence does not, by itself, establish the purity, stability or biological activity of a particular research preparation.

Discovery and Development of Ipamorelin

Ipamorelin was developed during research aimed at identifying growth hormone secretagogues with improved endocrine selectivity.

An important early study was published by Raun and colleagues in 1998 in the European Journal of Endocrinology.

The researchers described Ipamorelin as a potent GH secretagogue with a relatively selective endocrine response.

In experimental comparisons involving GHRP-2 and GHRP-6, Ipamorelin stimulated GH secretion without producing the same significant ACTH and cortisol responses observed with those peptides in the studied animal model.

This was an important finding for understanding the structure–activity relationships of growth hormone secretagogues.

However, endocrine selectivity in an animal study does not establish the absence of hormonal side effects in humans.

How Does Ipamorelin Work?

Ipamorelin acts as an agonist of the growth hormone secretagogue receptor.

This receptor is also called the ghrelin receptor or GHS-R1a.

GHS-R1a belongs to the G protein-coupled receptor family.

Receptor activation can initiate intracellular signaling involving phospholipase C and calcium mobilization.

Simplified Mechanism of Action

Ipamorelin

↓

GHS-R1a Receptor Binding

↓

Gq/11-Associated Signaling

↓

Phospholipase C Activation

↓

IP₃ and DAG Formation

↓

Intracellular Calcium Signaling

↓

Anterior Pituitary GH Secretion

↓

Downstream GH–IGF-1 Axis Responses

This pathway represents a simplified model of receptor-associated signaling.

Actual endocrine responses depend on physiological conditions, receptor expression, feedback regulation and experimental context.

Ipamorelin and the Ghrelin Receptor

Ghrelin is an endogenous hormone involved in growth hormone secretion and several metabolic processes.

Its principal signaling receptor is GHS-R1a.

The receptor is expressed in the hypothalamic–pituitary system and other tissues.

Ipamorelin has been investigated as a synthetic agonist at this receptor.

Research areas include:

Ligand–receptor interactions

G protein activation

Intracellular calcium signaling

Pituitary GH release

Receptor selectivity

Signal desensitization

Neuroendocrine feedback

Although Ipamorelin interacts with a receptor also involved in appetite regulation, it should not automatically be assumed to reproduce all the physiological effects of endogenous ghrelin.

Ipamorelin and Growth Hormone Secretion

Growth hormone secretion is regulated through coordinated hypothalamic and pituitary signaling.

GHRH stimulates GH release.

Somatostatin inhibits GH release.

Ghrelin receptor-associated signaling can also stimulate GH secretion.

Ipamorelin has demonstrated GH-releasing activity in experimental models.

Experimental Findings

Early investigations reported GH release in primary rat pituitary cell cultures.

Studies in rats and swine also demonstrated GH secretagogue activity.

These results established the compound as a useful experimental tool for investigating GH secretion.

Important Limitation

An acute increase in GH does not establish long-term improvements in muscle strength, fat mass, bone health or lifespan.

Clinical outcomes must be evaluated separately.

Ipamorelin and the GH–IGF-1 Axis

The growth hormone–insulin-like growth factor-1 axis is a central endocrine system involved in growth and metabolism.

Growth hormone stimulates IGF-1 production, particularly in the liver.

IGF-1 subsequently participates in tissue-specific growth and metabolic signaling.

Endocrine Pathway

Hypothalamus

↓

GHRH / Somatostatin / Ghrelin-Associated Regulation

↓

Anterior Pituitary

↓

Growth Hormone Release

↓

GH Receptor Activation

↓

Liver and Peripheral Tissues

↓

IGF-1 Regulation

↓

Growth and Metabolic Signaling

Ipamorelin acts upstream of the GH receptor by stimulating endogenous GH secretion.

This distinguishes it from recombinant HGH and direct IGF-1 receptor agonists.

Ipamorelin and Endocrine Selectivity

One of Ipamorelin's most frequently discussed characteristics is its endocrine selectivity.

In the original animal research, Ipamorelin produced a strong GH response without the same significant ACTH and cortisol stimulation observed with GHRP-2 and GHRP-6.

This finding is scientifically relevant because GH secretagogues can differ in their effects on pituitary hormone secretion.

Hormones Investigated

Growth Hormone (GH)

Adrenocorticotropic Hormone (ACTH)

Cortisol

Prolactin

Luteinizing Hormone (LH)

Follicle-Stimulating Hormone (FSH)

Thyroid-Stimulating Hormone (TSH)

Scientific Interpretation

Ipamorelin's selectivity was demonstrated under particular experimental conditions.

It should not be described as universally free of cortisol, prolactin or other endocrine effects.

Its full human endocrine safety profile remains insufficiently established.

Ipamorelin and ACTH Research

ACTH is secreted by the anterior pituitary gland and participates in the regulation of adrenal cortisol production.

Certain growth hormone secretagogues can influence ACTH secretion.

Early comparative studies found that GHRP-2 and GHRP-6 increased ACTH in the studied swine model.

Ipamorelin did not produce a similarly significant response under those experimental conditions.

This observation has made Ipamorelin relevant to research involving receptor selectivity.

However, absence of a significant response in one study does not establish absence of an effect across all species or physiological states.

Ipamorelin and Cortisol Research

Cortisol is a glucocorticoid hormone involved in metabolism, stress responses and immune regulation.

Some GH secretagogues influence cortisol-associated pathways.

Ipamorelin has been studied because of its comparatively selective GH-releasing activity in preclinical models.

Relevant research topics include:

ACTH–cortisol axis signaling

Pituitary receptor selectivity

Neuroendocrine responses

Hormonal feedback

Comparative peptide pharmacology

No conclusion about long-term cortisol safety in humans should be drawn from these findings alone.

Ipamorelin and Prolactin Research

Prolactin is a pituitary hormone with important reproductive and metabolic functions.

Several GH secretagogues have been investigated for their effects on prolactin secretion.

In early animal comparisons, Ipamorelin demonstrated relatively selective GH activity.

However, its effects on prolactin under all human physiological conditions have not been fully established.

The compound should not be promoted as guaranteed to have no effect on prolactin.

Ipamorelin and GH Pulsatility

Growth hormone secretion normally occurs in pulses.

These pulses are influenced by hypothalamic regulation, sleep, nutrition, age and other physiological variables.

Ipamorelin can stimulate acute GH release in responsive experimental systems.

However, this does not mean that its effects are identical to normal endogenous GH rhythms.

Relevant research areas include:

GH pulse amplitude

Secretory responsiveness

Pituitary reserve

Somatostatin interactions

Endocrine feedback

Receptor desensitization

The relationship between experimentally stimulated GH release and long-term endocrine outcomes remains complex.

Ipamorelin and Receptor Desensitization

G protein-coupled receptors can undergo changes in responsiveness following repeated stimulation.

These processes may involve:

Receptor phosphorylation

Beta-arrestin-associated regulation

Receptor internalization

Receptor recycling

Signal attenuation

Cellular adaptation

GHS-R1a is subject to receptor regulation.

Ipamorelin is relevant to research examining how synthetic agonists influence receptor signaling.

However, the extent and clinical relevance of receptor desensitization with Ipamorelin require further investigation.

Ipamorelin and Skeletal Muscle Research

The GH–IGF-1 axis participates in skeletal muscle physiology.

Growth hormone and IGF-1 are involved in protein metabolism and tissue growth regulation.

Because Ipamorelin stimulates GH release experimentally, it has attracted interest in muscle-related research.

Relevant scientific topics include:

GH secretion

IGF-1 regulation

Muscle protein metabolism

Endocrine responses to exercise

Cellular growth signaling

Body composition physiology

Evidence Limitation

There is insufficient high-quality clinical evidence demonstrating that Ipamorelin improves muscle mass, strength or athletic performance in healthy humans.

An acute GH response is not equivalent to a proven anabolic effect.

Ipamorelin and Body Composition Research

Growth hormone influences lipid and protein metabolism.

This has generated scientific interest in GH secretagogues and body composition.

Ipamorelin-related research may examine:

GH-associated metabolic signaling

Lipid metabolism

Protein turnover

IGF-1 regulation

Endocrine feedback

Body composition markers

However, no reliable clinical evidence establishes Ipamorelin as an effective weight-loss or fat-reduction treatment.

Changes in hormone concentrations should not be presented as proven changes in body composition.

Ipamorelin and Glucose Metabolism

Growth hormone can influence insulin sensitivity and glucose regulation.

Because Ipamorelin stimulates GH secretion, metabolic effects are an important area of scientific consideration.

Relevant research endpoints include:

Blood glucose regulation

Insulin sensitivity

GH-associated metabolic responses

Lipid mobilization

Energy substrate utilization

IGF-1-associated feedback

GH-related signaling can reduce insulin sensitivity under certain conditions.

Therefore, Ipamorelin should not be described as metabolically risk-free.

Its long-term effects on glucose regulation in humans remain insufficiently characterized.

Ipamorelin and Bone Research

Growth hormone and IGF-1 participate in bone growth and remodeling.

These endocrine pathways influence osteoblasts, chondrocytes and other skeletal cell populations.

Ipamorelin may be relevant to experimental studies involving GH-associated bone physiology.

Research areas include:

Bone metabolism

Osteoblast signaling

IGF-1 regulation

Growth plate physiology

Skeletal development

Bone remodeling

However, there is no established clinical evidence that Ipamorelin improves bone mineral density or prevents fractures in humans.

Ipamorelin and Connective Tissue Research

GH and IGF-1 signaling participate in processes relevant to connective tissue biology.

Research involving Ipamorelin may explore endocrine regulation of:

Collagen metabolism

Extracellular matrix signaling

Tendon-associated physiology

Ligament biology

Tissue remodeling

Growth factor responses

However, Ipamorelin has not been clinically established to accelerate wound healing, repair injuries or improve tendon and ligament strength.

Ipamorelin and Sleep Research

Growth hormone secretion is associated with sleep physiology.

In many individuals, a prominent GH pulse occurs during early nocturnal sleep.

Because Ipamorelin influences GH secretion, it is relevant to investigations of endocrine rhythms.

Research topics include:

Sleep-associated GH pulses

Hypothalamic signaling

Pituitary responsiveness

Circadian endocrine regulation

Somatostatin activity

GH secretory dynamics

However, Ipamorelin has not been established as a safe or effective treatment for insomnia or poor sleep quality.

Ipamorelin and Aging Research

GH and IGF-1 concentrations change with age.

This has generated interest in the relationship between endocrine signaling and aging.

Ipamorelin may be discussed in research involving age-related GH secretion.

However, age-associated endocrine changes do not automatically indicate a medical disorder.

Important Evidence Limitations

Ipamorelin has not been shown to reverse biological aging.

It has not been demonstrated to extend human lifespan.

It has not been established to prevent age-related disease.

Its long-term safety in older adults remains insufficiently characterized.

Ipamorelin and Gastrointestinal Motility Research

Beyond GH secretion, Ipamorelin has been investigated in gastrointestinal motility research.

Ghrelin receptor signaling is relevant to gastrointestinal physiology.

Clinical development programs explored Ipamorelin in postoperative gastrointestinal dysfunction, including postoperative ileus.

These studies are important because they demonstrate that Ipamorelin has been investigated for endpoints other than GH release.

However, research into postoperative gastrointestinal motility did not establish Ipamorelin as a generally approved treatment.

The clinical development history also raises important safety considerations.

Ipamorelin and Postoperative Ileus

Postoperative ileus refers to impaired gastrointestinal motility following surgery.

It can delay recovery of normal bowel function.

Ghrelin receptor agonists have been investigated because of their potential influence on gastrointestinal motility.

Ipamorelin was studied in this context.

However, available clinical research did not establish a sufficiently supported benefit–risk profile for routine therapeutic use.

The FDA has identified serious adverse events, including deaths, in a clinical study involving intravenous Ipamorelin for gastrointestinal motility.

Those reports do not, by themselves, establish that Ipamorelin caused every reported event, but they reinforce the need for caution.

Ipamorelin and Peptide Structure–Activity Relationships

Structure–activity relationship (SAR) research investigates how molecular modifications affect biological function.

Ipamorelin contains several structural features relevant to receptor pharmacology.

These include:

Aib at Position 1

Histidine at Position 2

D-2-Naphthylalanine at Position 3

D-Phenylalanine at Position 4

Lysine at Position 5

C-Terminal Amidation

Researchers can use these features to investigate relationships between peptide structure, receptor binding and endocrine activity.

Ipamorelin's development contributed to understanding how synthetic peptide design can influence hormonal selectivity.

Ipamorelin vs. GHRP-2

Ipamorelin and GHRP-2 are both synthetic growth hormone secretagogues.

Both stimulate GH release through GHS-R1a-associated mechanisms.

However, their molecular structures and endocrine response profiles differ.

The comparative endocrine findings should not be interpreted as proof that Ipamorelin has no hormonal adverse effects.

Ipamorelin vs. GHRP-6

GHRP-6 is a synthetic hexapeptide that stimulates GH secretion through ghrelin receptor-associated signaling.

Ipamorelin is a pentapeptide with a different amino acid sequence.

Main Research Differences

Ipamorelin: Investigated for selective GH release.

GHRP-6: Investigated for GH release and broader ghrelin-associated physiological responses.

In the original comparative research, GHRP-6 stimulated ACTH and cortisol more noticeably than Ipamorelin in the studied swine model.

However, both compounds remain experimental for many proposed applications.

Neither has established clinical efficacy for bodybuilding, fat loss or anti-aging.

Ipamorelin vs. Hexarelin

Hexarelin, also known as Examorelin, is another synthetic GH secretagogue.

Hexarelin is a hexapeptide, while Ipamorelin is a pentapeptide.

Both interact with GHS-R1a-associated signaling.

Hexarelin has also been investigated in cardiovascular research and CD36-associated binding studies.

Ipamorelin has been particularly associated with endocrine selectivity research.

Findings from one compound should not automatically be applied to the other.

Ipamorelin vs. CJC-1295

Ipamorelin and CJC-1295 act through different upstream mechanisms of the GH axis.

Ipamorelin activates the ghrelin receptor.

CJC-1295 is a modified growth hormone-releasing hormone analogue that activates the GHRH receptor.

Although the two receptor systems participate in GH regulation, the safety and effectiveness of combining experimental compounds have not been established.

Ipamorelin vs. Sermorelin

Sermorelin is a synthetic analogue of the N-terminal portion of GHRH.

It activates the GHRH receptor.

Ipamorelin activates GHS-R1a.

These receptors belong to different signaling systems.

Sermorelin and Ipamorelin should therefore not be described as identical or interchangeable compounds.

Their research evidence and regulatory histories also differ.

Ipamorelin vs. HGH 191AA

Ipamorelin and HGH 191AA affect the GH axis at different points.

Ipamorelin stimulates endogenous GH secretion.

HGH 191AA is the full-length human growth hormone protein.

A GH secretagogue is not equivalent to recombinant growth hormone.

Ipamorelin vs. MK-677 (Ibutamoren)

MK-677, also called Ibutamoren, is a nonpeptide growth hormone secretagogue.

It acts through GHS-R1a-associated signaling.

Ipamorelin is a peptide.

The two compounds have different pharmacological properties.

Their clinical effects and risks cannot be assumed to be identical.

Ipamorelin and Human Clinical Evidence

Ipamorelin has a substantial preclinical research history and a more limited clinical development history.

Preclinical Evidence

Early studies demonstrated GH secretion in rat pituitary cell cultures and animal models.

Comparative animal research also identified relatively selective GH stimulation.

Human Research

Ipamorelin has been investigated clinically, including in gastrointestinal motility research.

However, these studies do not establish its efficacy for common commercial claims involving muscle growth, body composition, recovery or anti-aging.

Clinical Evidence Limitations

There is no established evidence that Ipamorelin:

• Produces clinically meaningful muscle growth in healthy humans.

• Improves athletic performance.

• Causes sustained fat loss.

• Reverses biological aging.

• Extends human lifespan.

• Prevents age-related diseases.

• Improves sleep quality as a proven therapy.

• Provides safe long-term endocrine enhancement.

Its human pharmacokinetic, endocrine and long-term safety profiles remain insufficiently characterized for these applications.

Potential Safety Concerns

Ipamorelin is a biologically active GH secretagogue.

Its long-term safety in humans is not established.

Important scientific concerns include:

Endocrine Effects

Stimulation of GH secretion may influence multiple hormonal feedback systems.

Glucose Regulation

GH-associated signaling can influence insulin sensitivity and blood glucose.

Fluid Retention

GH-related physiological effects may raise concerns about fluid balance.

Unknown Long-Term Effects

There are insufficient data to establish the consequences of prolonged exposure.

Receptor-Mediated Effects

GHS-R1a is expressed in multiple tissues, so biological responses may extend beyond pituitary GH release.

Immunogenicity

Peptide aggregation and peptide-related impurities can create immunogenicity concerns.

Product Characterization

Ipamorelin contains nonstandard amino acids, increasing the complexity of analytical characterization.

Clinical Adverse Events

The FDA has highlighted serious adverse events, including deaths, reported in a clinical study involving intravenous Ipamorelin for gastrointestinal motility. Causality for individual events should not be assumed without appropriate analysis.

Unverified Research Preparations

Research-grade products may not meet the manufacturing, sterility and safety requirements of licensed pharmaceuticals.

These concerns make unsupervised human use inappropriate.

Ipamorelin and FDA Regulatory Considerations

Ipamorelin is not an FDA-approved human therapeutic drug.

The FDA has specifically identified safety concerns involving compounded Ipamorelin acetate.

These include:

Potential immunogenicity

Peptide aggregation

Peptide-related impurities

Complexities in characterizing nonstandard amino acids

Insufficient safety information for certain administration routes

Serious adverse events reported during clinical development

The regulatory status of compounded drugs is not equivalent to approval of a finished pharmaceutical product.

A research-use label does not establish that a product is suitable for clinical administration.

Ipamorelin and Anti-Doping Regulations

Ipamorelin is prohibited under the World Anti-Doping Agency (WADA) framework.

It belongs to the category of growth hormone secretagogues and their mimetics.

The prohibition applies in and out of competition.

Athletes should not assume that a research-use product is exempt from anti-doping restrictions.

Applicable regulations should always be checked against the current WADA Prohibited List.

Scientific Evidence and Research Limitations

Ipamorelin has demonstrated biological activity in experimental endocrine models.

However, the strength of evidence varies by application.

Established Scientific Findings

• Ipamorelin is a synthetic pentapeptide.

• Its sequence is Aib–His–D-2-Nal–D-Phe–Lys–NH₂.

• It acts through growth hormone secretagogue receptor-associated signaling.

• It stimulates GH release in preclinical models.

• Early animal studies demonstrated relatively selective GH secretion.

• It has been investigated in gastrointestinal motility research.

• It is structurally distinct from GHRP-2, GHRP-6 and Hexarelin.

• It is prohibited under WADA anti-doping regulations.

Important Limitations

• Human therapeutic efficacy is not established.

• Long-term endocrine safety is unknown.

• Body composition benefits in healthy humans are unproven.

• Muscle-building benefits are unproven.

• Anti-aging and longevity claims are unsupported.

• Preclinical endocrine selectivity does not guarantee clinical safety.

• Human metabolic risks are insufficiently characterized.

• Clinical development has raised significant safety concerns.

• Research-grade Ipamorelin is not an approved pharmaceutical treatment.

Potential Research Applications

Ipamorelin may be relevant to appropriately controlled scientific investigations involving:

• Growth hormone secretagogue receptor biology

• GHS-R1a pharmacology

• Ghrelin receptor signaling

• Gq/11-associated pathways

• Phospholipase C signaling

• Intracellular calcium mobilization

• Pituitary GH secretion

• GH–IGF-1 axis physiology

• Hypothalamic–pituitary communication

• Endocrine selectivity

• ACTH response comparisons

• Cortisol response comparisons

• Prolactin-associated research

• Growth hormone pulsatility

• Receptor desensitization

• Peptide structure–activity relationships

• Neuroendocrine pharmacology

• Gastrointestinal motility research

• GH-associated metabolic physiology

• Comparative growth hormone secretagogue research

These are research applications, not established therapeutic benefits.

Ipamorelin Research Overview

Compound Name: Ipamorelin

Development Code: NNC 26-0161

Classification: Synthetic Growth Hormone Secretagogue

Peptide Length: 5 Amino Acid Residues

Sequence: Aib–His–D-2-Nal–D-Phe–Lys–NH₂

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: Approximately 711.9 g/mol

CAS Number: 170851-70-4

Primary Receptor: GHS-R1a

Receptor Type: G Protein-Coupled Receptor

Principal Signaling: Gq/11–PLC–IP₃/DAG–Ca²⁺

Primary Research Endpoint: GH Secretion

Related Endocrine Axis: GH–IGF-1

Main Research Fields: Endocrinology / Receptor Pharmacology / Peptide Biology

Established Human Therapeutic Efficacy: None

FDA Approval: Not approved as a human therapeutic drug

Intended Product Use: Laboratory Research Only

Anti-Doping Status: Prohibited under WADA rules

Product Information

Product Name: Ipamorelin

Alternative Name: NNC 26-0161

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: Growth Hormone Secretagogue

Research Areas: GHS-R1a / GH Secretion / GH–IGF-1 Axis / Neuroendocrine Signaling

Intended Use: Laboratory Research & Development Only

The identity and specifications of the supplied research material should be confirmed through batch-specific manufacturer documentation.

Relevant analytical information includes:

• Verified peptide sequence

• Molecular identity

• Peptide purity

• Peptide content

• Salt form and counterion

• Impurity profile

• Analytical methodology

• Certificate of Analysis (COA)

• Batch/lot identification

• Validated storage conditions

No claims of pharmaceutical quality, sterility, injectable suitability or clinical efficacy should be made without appropriate supporting documentation and regulatory authorization.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, bodybuilding, performance-enhancing, anti-aging, weight-loss or other clinical purposes. Not for direct administration to humans or animals.

Ipamorelin is a biologically active growth hormone secretagogue.

It stimulates GH secretion in experimental systems through ghrelin receptor-associated signaling.

Its human clinical efficacy and long-term systemic safety have not been established.

Potential risks include endocrine and metabolic effects, peptide-related impurities and immunogenicity.

The FDA has identified significant safety concerns associated with compounded Ipamorelin acetate.

Ipamorelin is prohibited in sport under WADA regulations.

Information presented on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, endocrinology, growth hormone research, receptor signaling and experimental pharmacology.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.

Frequently Asked Questions About Ipamorelin

What is Ipamorelin?

Ipamorelin is a synthetic five-amino-acid growth hormone secretagogue investigated for its ability to stimulate endogenous GH secretion.

How many amino acids does Ipamorelin contain?

Ipamorelin contains five amino acid residues.

What is the amino acid sequence of Ipamorelin?

Aib–His–D-2-Nal–D-Phe–Lys–NH₂.

What is the molecular weight of Ipamorelin?

The free peptide has an approximate molecular weight of 711.9 g/mol.

What is the CAS number of Ipamorelin?

170851-70-4.

What receptor does Ipamorelin activate?

Ipamorelin primarily activates the growth hormone secretagogue receptor, GHS-R1a.

How does Ipamorelin stimulate growth hormone?

It activates ghrelin receptor-associated signaling that can stimulate GH secretion from the anterior pituitary.

Is Ipamorelin the same as HGH?

No. Ipamorelin stimulates endogenous GH secretion, while HGH is the growth hormone protein itself.

Is Ipamorelin the same as GHRP-2?

No. Both are GH secretagogues, but they have different molecular structures and endocrine response profiles.

Is Ipamorelin more selective than GHRP-6?

Early animal research demonstrated relatively selective GH secretion with Ipamorelin compared with GHRP-6. This does not prove that Ipamorelin has fewer clinical adverse effects in humans.

Does Ipamorelin increase cortisol?

In the original comparative swine study, Ipamorelin did not significantly increase ACTH or cortisol under the studied conditions. Its effects across all human settings are not established.

Does Ipamorelin increase muscle mass?

There is insufficient clinical evidence establishing meaningful muscle growth or strength improvements in healthy humans.

Does Ipamorelin reduce body fat?

No established clinical evidence demonstrates that Ipamorelin produces sustained fat loss in humans.

Is Ipamorelin an anti-aging peptide?

Ipamorelin has not been shown to reverse aging or extend human lifespan.

Is Ipamorelin approved by the FDA?

No. Ipamorelin is not an FDA-approved human therapeutic drug.

Is Ipamorelin prohibited in sport?

Yes. Ipamorelin is prohibited under WADA anti-doping regulations.

Is ICAME Pharmacy Ipamorelin intended for human use?

No. ICAME Pharmacy Ipamorelin is intended strictly for laboratory research and development purposes.